J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B
Executive Summary
The pharma is paying $250m up front for worldwide rights to Arrowhead’s Phase I/II RNAi candidate. Arrowhead says letting J&J take the lead on HBV enables it to focus on other pipeline programs it can bring to market itself.
You may also be interested in...
GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development
Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.
Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J
J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.
Big Pharma Pacts Benefit From Reduced HBV Biologics Competition
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.